On September 1, 2021 Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported that the Company will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021 (Press release, Lipocine, SEP 1, 2021, https://www.prnewswire.com/news-releases/lipocine-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301366743.html [SID1234587138]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Presentation time: September 13, 2021 starting at 7:00 a.m. EST
Webcast link: View Source

A webcast of Lipocine’s presentation will be available on-demand as of 7:00 am ET, Monday, September 13, 2021, thorough the H.C. Wainwright conference portal, on Lipocine’s website under "Events & Presentations" in the Investors section or using the webcast link above. The webcast will be available on the Lipocine’s website for 90 days.